This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
by Zacks Equity Research
TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
by Zacks Equity Research
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion
by Zacks Equity Research
Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.
FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector
by Zacks Equity Research
With FDA platform technology designation for its viral vector, SRPT can fast-track other therapies using the same gene-delivery method.
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
by Zacks Equity Research
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
by Zacks Equity Research
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
by Zacks Equity Research
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
by Zacks Equity Research
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
by Zacks Equity Research
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 36.02% and 14.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 33.33% and 5.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
by Zacks Equity Research
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
by Zacks Equity Research
ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 13.56% and 20.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Agilent Q1 Earnings Beat Estimates, Stock Falls on Cautious FY25 View
by Zacks Equity Research
A's first-quarter fiscal 2025 results benefit from strong LC & services, but margin contraction raises investor concerns.
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?